{
    "clinical_study": {
        "@rank": "74141", 
        "brief_summary": {
            "textblock": "To characterize the safety and efficacy of ReFacto AF in treating acute bleeding episodes\n      during prophylaxis treatment, including neoantigenicity."
        }, 
        "brief_title": "Study Evaluating ReFacto AF in Severe Hemophilia A", 
        "completion_date": {
            "#text": "August 2004", 
            "@type": "Actual"
        }, 
        "condition": "Hemophilia A", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Severe hemophilia A (FVIII:C less than or equal to 2% at local laboratory)\n\n          -  Previously treated patients with greater than or equal to 250 exposure days to any\n             Factor VIII product\n\n          -  Age greater than or equal to 12 years\n\n          -  History of prophylaxis dosing at least twice per week on any Factor VIII product for\n             at least 3 consecutive months within the 2 years prior to study enrollment unless the\n             patient completed the previous pharmacokinetic study\n\n          -  Adequate laboratory results\n\n        Exclusion Criteria:\n\n          -  Presence of any bleeding disorder in addition to hemophilia A\n\n          -  Concomitant therapy with immunosuppressive drugs\n\n          -  Current or historical Factor VIII inhibitor\n\n          -  Treatment with any investigational drug or device within the past 30 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "firstreceived_date": "May 17, 2002", 
        "id_info": {
            "nct_id": "NCT00037544", 
            "org_study_id": "3082B1-306"
        }, 
        "intervention": {
            "intervention_name": "ReFacto AF", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "keyword": [
            "Severe", 
            "Hemophilia", 
            "A"
        ], 
        "lastchanged_date": "April 18, 2008", 
        "official_title": "An Open-Label Study to Characterize the Safety and Efficacy of BDDrFVIII Manufactured by the Albumin Free Process (ReFacto AF) in the Treatment of Previously Treated Patients (PTP) With Severe Hemophilia A", 
        "overall_official": {
            "affiliation": "Wyeth is now a wholly owned subsidiary of Pfizer", 
            "last_name": "Medical Monitor, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2004", 
            "@type": "Actual"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00037544"
        }, 
        "source": "Wyeth is now a wholly owned subsidiary of Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wyeth is now a wholly owned subsidiary of Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2008"
    }, 
    "geocoordinates": {}
}